(c)
| Change in GFR (mL/min/1.73 m2) after conversion | Change in serum creatinine concentration (µmol/L) after conversion | Change in CrCl (mL/min) from baseline at postconversion time point | ||||||
|---|---|---|---|---|---|---|---|---|
| 6 months | 1 year | Other time points | 3 months | 6 months | 1 year | 6 months | 1 year | |
| Early conversion (≤3 months after transplantation) | ||||||||
| Fischer et al. Am J Transplant. 2012; 12: 1855–65 [50] | 11-month data (EVR versus CNI): CG-GFR: mean change from baseline: + 4.4 ± 27.1 versus 0.9 ± 29.2 LS mean difference ±SE: −2.923 ± 3.920 (P=0.457)§ MDRD-GFR: mean change from baseline: +2.0 ± 23.2 versus −2.8 ± 23.1LS mean difference ± SE: −7.778 ± 3.338 (P=0.021)§ |
|||||||
| Schlitt et al. AASLD 2012 [91] | 35 months: difference in eGFR between EVR and CNI: Cockcroft-Gault: −10.5 mL/min (P = 0.096) and Nankivell formula: −10.5 mL/min (P = 0.015) | |||||||
| Masetti et al. Am J Transplant. 2010; 10: 2252–62 [89] | +6.1 versus −16.5 (EVR versus CsA, P < 0.001 comparison of absolute values) | +5.9 versus −14.8 (EVR versus CsA, P < 0.001 comparison of absolute values) | ||||||
| De Simone et al. Am J Transplant. 2012; 12: 3008–20 [87] | EVR + TAC-RD (adjusted mean difference in eGFR change for EVR + TAC-RD versus TAC-SD: +8.50 ± 2.12; P < 0.001) | |||||||
| Saliba et al. AASLD 2012 [90] | 24 months: EVR + TAC-RD versus TAC-SD: mean difference in eGFR change: +6.66 (97.5% CI: +1.9, + 11.42; P = 0.0018) |
|||||||
|
| ||||||||
| Late conversion (>3 months after transplantation) | ||||||||
| Castroagudín et al. Liver Transpl. 2009; 15: 1792–7 [94] | +3.99 (NS versus baseline) | +7.65 (P = 0.016 versus baseline) | −0.09 (NS versus baseline) | −0.22‡ (P < 0.05 versus baseline) | +5.18 (NS versus baseline) | +9.82 (P = 0.025 versus baseline) | ||
| De Simone et al. Transpl Int. 2009; 22: 279–86 [95] | +4.03 | |||||||
| De Simone et al. Liver Transpl. 2009; 15: 1262–9 [96] | EVR: +1.0; controls: +2.3 (NS) | |||||||
| Saliba et al. Liver Transpl. 2011; 17: 905–13 [98] | +6.6 chronic renal failure subpopulation versus baseline (P = 0.0002) | +4.2 overall versus baseline (P = 0.007) +8.6 chronic renal failure subpopulation versus baseline (P = 0.02) |
−11 versus baseline (P = 0.04) | −9 versus baseline (P = NS) | −6 versus baseline (P = NS) | |||
P values are included where available.
*Median eGFR; †mL/min; ‡mg/dL.
§Between-group difference (calculated as CNI group minus everolimus group) at month 11 after baseline; results based on ANCOVA model.
CG-GFR: GFR calculated with the Cockcroft-Gault formula; CNI: calcineurin inhibitor; CrCl: creatinine clearance; CsA: cyclosporin A; EVR: everolimus; GFR: glomerular filtration rate; LS: least square; MDRD: modification of diet in renal disease; MDRD-GFR: GFR calculated using the MDRD formula; NS: nonsignificant; SE: standard error; TAC-RD: reduced-dose tacrolimus (C0: 3–5 ng/mL); TAC-SD: standard-dose tacrolimus (C0: 6–10 ng/mL).